Chromogranin B and secretogranin II in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations and in Alzheimer patients

Journal of Alzheimer's Disease

Volumn 13, Issue 2, 2008, Pages 123-135

  Willis, Michael ^a   Prokesch, Manuela ^b   Hutter Paier, Birgit ^b   Windisch, Manfred ^b   Stridsberg, Mats ^c   Mahata, Sushil K ^d   Kirchmair, Rudolf ^e   Wietzorrek, Georg ^a   Knaus, Hans Günther ^a   Jellinger, Kurt ^f   Humpel, Christian ^a   Marksteiner, Josef ^g  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b JSW Life Sciences GmbH   (Austria)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

^g GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

Alphabetize: amyloid beta; Chromogranin B; Large dense core vesicles; Secretogranin II; Transgenic

Indexed keywords

AMYLOID BETA PROTEIN PRECURSOR APP751; AMYLOID PRECURSOR PROTEIN; CHROMOGRANIN B; SECRETOGRANIN II; AMYLOID BETA PROTEIN; ASPARTIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; ISOLEUCINE; LEUCINE; METHIONINE; SUBSTANCE P; VALINE;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; MAZE TEST; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TASK PERFORMANCE; TRANSGENIC MOUSE; ANIMAL; BRAIN; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; POINT MUTATION;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASPARTIC ACID; BRAIN; CHROMOGRANIN B; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; ISOLEUCINE; LEUCINE; METHIONINE; MICE; MICE, TRANSGENIC; POINT MUTATION; SECRETOGRANIN II; SUBSTANCE P; VALINE;

EID: 44849134960     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2008-13202     Document Type: Article

References (54)

1. T.A. Bayer, O. Wirths, K. Majtenyi, T. Hartmann, G. Multhaup, K. Beyreuther and C. Czech, Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport, Brain Pathol 11 (2001), 1-11.
2. M. Bergmann, K. Kuchelmeister, K.W. Schmid, H.A. Kretzschmar and R. Schroder, Different variants of frontotemporal dementia: a neuropathological and immunohistochemical study, Acta Neuropathol (Berl) 92 (1996), 170-179.
3. N. Beuret, H. Stettler, A. Renold, J. Rutishauser and M. Spiess, Expression of regulated secretory proteins is sufficient to generate granule-like structures in constitutively secreting cells, J Biol Chem 279 (2004), 20242-20249.
4. L. Bondolfi, F. Ermini, J.M. Long, D.K. Ingram and M. Jucker, Impact of age and caloric restriction on neurogenesis in the dentate gyrus of C57BL/6 mice, Neurobiol Aging 25 (2004), 333-340.
5. M.L. Cordeiro, J.A. Umbach and C.B. Gundersen, Lithium ions Up-regulate mRNAs encoding dense-core vesicle proteins in nerve growth factor-differentiated PC12 cells, J Neurochem 75 (2000), 2622-2625.
6. T.C. Dickson, C.E. King, G.H. McCormack and J.C. Vickers, Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer's disease, Exp Neurol 156 (1999), 100-110.
7. H. Dong, M.V. Martin, S. Chambers and J.G. Csernansky, Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice, J Comp Neurol 500 (2007), 311-321.
8. I. Ferrer, E. Marti, A. Tortosa and J. Blasi, Dystrophic neurites of senile plaques are defective in proteins involved in exocytosis and neurotransmission, J Neuropathol Exp Neurol 57 (1998), 218-225.
9. R. Fischer-Colbrie, S. Eder, P. Lovisetti-Scamihorn, A. Becker and A. Laslop, Neuroendocrine secretory protein 55: a novel marker for the constitutive secretory pathway, Ann N Y Acad Sci 971 (2002), 317-322.
10. R. Fischer-Colbrie, R. Kirchmair, A. Schobert, C. Olenik, D.K. Meyer and H. Winkler, Secretogranin II is synthesized and secreted in astrocyte cultures, J Neurochem 60 (1993), 2312-2314.
11. G.K. Gouras, C.G. Almeida and R.H. Takahashi, Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease, Neurobiol Aging 26 (2005), 1235-1244.
12. J. Hardy and D.J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science 297 (2002), 353-356.
13. K.B. Helle, The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects, Biological Reviews 79 (2004), 769-794.
14. C. Hooper and J.M. Pocock, Chromogranin A activates diverse pathways mediating inducible nitric oxide expression and apoptosis in primary microglia, Neurosci Lett 413 (2007), 227-232.
15. C.M. Huang, H.A. Shui, Y.T. Wu, P.W. Chu, K.G. Lin, L.S. Kao and S.T. Chen, Proteomic analysis of proteins in PC12 cells before and after treatment with nerve growth factor: increased levels of a 43-kDa chromogranin B-derived fragment during neuronal differentiation, Brain Res Mol Brain Res 92 (2001), 181-192.
16. B. Hutter-Paier, H.J. Huttunen, L. Puglielli, C.B. Eckman, D.Y. Kim, A. Hofmeister, R.D. Moir, S.B. Domnitz, M.P. Frosch, M. Windisch and D.M. Kovacs, The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease, Neuron 44 (2004), 227-238.
17. J.S. Jacobsen, C.C. Wu, J.M. Redwine, T.A. Comery, R. Arias, M. Bowlby, R. Martone, J.H. Morrison, M.N. Pangalos, P.H. Reinhart and F.E. Bloom, Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease, Proc Natl Acad Sci USA 103 (2006), 5161-5166.
18. K.A. Jellinger and C. Bancher, Neuropathology of Alzheimer's disease: a critical update, J Neural Transm Suppl 54 (1998), 77-95.
19. W.A. Kaufmann, U. Barnas, C. Humpel, K. Nowakowski, C. DeCol, P. Gurka, G. Ransmayr, H. Hinterhuber, H. Winkler and J. Marksteiner, Synaptic loss reflected by secretoneurin-like immunoreactivity in the human hippocampus in Alzheimer's disease, Eur J Neurosci 10 (1998), 1084-1094.
20. Z.S. Khachaturian, Diagnosis of Alzheimer's disease, Arch Neurol 42 (1985), 1097-1105.
21. R. Kirchmair, M. Egger, D.H. Walter, W. Eisterer, A. Niederwanger, E. Woell, M. Nagl, M. Pedrini, T. Murayama, S. Frauscher, A. Hanley, M. Silver, M. Brodmann, W. Sturm, R. Fischer-Colbrie, D.W. Losordo, J.R. Patsch and P. Schratzberger, Secretoneurin, an angiogenic neuropeptide, induces postnatal vasculogenesis, Circulation 110 (2004), 1121-1127.
22. M. Landen, B. Grenfeldt, P. Davidsson, M. Stridsberg, B. Regland, C.G. Gottfries and K. Blennow, Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia, Eur Neuropsychopharmacol 9 (1999), 311-315.
23. H. Lassmann, P. Fischer and K. Jellinger, Synaptic pathology of Alzheimer's disease, Ann N Y Acad Sci 695 (1993), 59-64.
24. H. Lassmann, R. Weiler, P. Fischer, C. Bancher, K. Jellinger, E. Floor, W. Danielczyk, F. Seitelberger and H. Winkler, Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles, Neuroscience 46 (1992), 1-8.
25. T. Lechner, C. Adlassnig, C. Humpel, W.A. Kaufmann, H. Maier, K. Reinstadler-Kramer, J. Hinterholzl, S.K. Mahata, K.A. Jellinger and J. Marksteiner, Chromogranin peptides in Alzheimer's disease, Exp Gerontol 39 (2004), 101-113.
26. N.R. Mahapatra, M. Mahata, S. Ghosh, J.R. Gayen, D.T. O'Connor and S.K. Mahata, Molecular basis of neuroendocrine cell type-specific expression of the chromogranin B gene: Crucial role of the transcription factors CREB, AP-2, Egr-1 and Sp1, J Neurochem 99 (2006), 119-133.
27. J. Marksteiner, R. Bauer, W.A. Kaufmann, E. Weiss, U. Barnas and H. Maier, PE-11, a peptide derived from chromogranin B, in the human brain, Neuroscience 91 (1999), 1155-1170.
28. J. Marksteiner, W.A. Kaufmann, P. Gurka and C. Humpel, Synaptic proteins in Alzheimer's disease, J Mol Neurosci 18 (2002), 53-63.
29. J. Marksteiner, T. Lechner, W.A. Kaufmann, P. Gurka, C. Humpel, C. Nowakowski, H. Maier and K.A. Jellinger, Distribution of chromogranin B-like immunoreactivity in the human hippocampus and its changes in Alzheimer's disease, Acta Neuropathol (Berl) 100 (2000), 205-212.
30. J. Marksteiner, A. Saria, R. Kirchmair, R. Pycha, H. Benesch, R. Fischer-Colbrie, C. Haring, H. Maier and G. Ransmayr, Distribution of secretoneurin-like immunoreactivity in comparison with substance P- and enkephalin-like immunoreactivities in various human forebrain regions, Eur J Neurosci 5 (1993), 1573-1585.
31. E. Masliah, A. Sisk, M. Mallory, L. Mucke, D. Schenk and D. Games, Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease, J Neurosci 16 (1996), 5795-5811.
32. S.S. Mirra, Neuropathological assessment of Alzheimer's disease: the experience of the Consortium to Establish a Registry for Alzheimer's Disease, Int Psychogeriatr 9(Suppl 1) (1997), 263-268.
33. J.C. Morris, The Clinical Dementia Rating (CDR): current version and scoring rules, Neurology 43 (1993), 2412-2414.
34. D.G. Munoz, The distribution of chromogranin A-like immunoreactivity in the human hippocampus coincides with the pattern of resistance to epilepsy-induced neuronal damage, Ann Neurol 27 (1990), 266-275.
35. S. Natori, A. King, A. Hellwig, U. Weiss, H. Iguchi, B. Tsuchiya, T. Kameya, R. Takayanagi, H. Nawata and W.B. Huttner, Chromogranin B (secretogranin I), a neuroendocrine-regulated secretory protein, is sorted to exocrine secretory granules in transgenic mice, EMBO J 17 (1998), 3277-3289.
36. C. Nowakowski, W.A. Kaufmann, C. Adlassnig, H. Maier, K. Salimi, K.A. Jellinger and J. Marksteiner, Reduction of chromogranin B-like immunoreactivity in distinct subregions of the hippocampus from individuals with schizophrenia, Schizophr Res 58 (2002), 43-53.
37. S. Oddo, A. Caccamo, I.F. Smith, K.N. Green and F.M. LaFerla, A dynamic relationship between intracellular and extracellular pools of Abeta, Am J Pathol 168 (2006), 184-194.
38. G. Paxinos and K.B.J. Franklin, The Mouse Brain in Stereotaxic Coordinates, Academic Press, San Diego, 2001.
39. E. Rockenstein, M. Mallory, M. Mante, A. Sisk and E. Masliaha, Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42), J Neurosci Res 66 (2001), 573-582.
40. P.J. Shen and A.L. Gundlach, Differential increases in chromogranins, but not synapsin I, in cortical neurons following spreading depression: implications for functional roles and transmitter peptide release, Eur J Neurosci 10 (1998), 2217-2230.
41. C. Sturchler-Pierrat, D. Abramowski, M. Duke, K.H. Wiederhold, C. Mistl, S. Rothacher, B. Ledermann, K. Burki, P. Frey, P.A. Paganetti, C. Waridel, M.E. Calhoun, M. Jucker, A. Probst, M. Staufenbiel and B. Sommer, Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology, Proc Natl Acad Sci USA 94 (1997), 13287-13292.
42. Y. Su, J. Ryder, B. Li, X. Wu, N. Fox, P. Solenberg, K. Brune, S. Paul, Y. Zhou, F. Liu and B. Ni, Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing, Biochemistry 43 (2004), 6899-6908.
43. R.H. Takahashi, C.G. Almeida, P.F. Kearney, F. Yu, M.T. Lin, T.A. Milner and G.K. Gouras, Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain, J Neurosci 24 (2004), 3592-3599.
44. L. Taupenot, K.L. Harper and D.T. O'Connor, The chromogranin- secretogranin family, N Engl J Med 348 (2003), 1134-1149.
45. D.L. Taylor, L.T. Diemel, M.L. Cuzner and J.M. Pocock, Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer's disease, J Neurochem 82 (2002), 1179-1191.
46. R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, L.A. Hansen and R. Katzman, Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment, Ann Neurol 30 (1991), 572-580.
47. E.C. Thrower, C.U. Choe, S.H. So, S.H. Jeon, B.E. Ehrlich and S.H. Yoo, A functional interaction between chromogranin B and the inositol 1,4,5-trisphosphate receptor/Ca2+ channel, J Biol Chem 278 (2003), 49699-49706.
48. M.C. Tierney, R.H. Fisher, A.J. Lewis, M.L. Zorzitto, W.G. Snow, D.W. Reid and P. Nieuwstraten, The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases, Neurology 38 (1988), 359-364.
49. F. Torrealba and M.A. Carrasco, A review on electron microscopy and neurotransmitter systems, Brain Res Brain Res Rev 47 (2004), 5-17.
50. M. Urushitani, A. Sik, T. Sakurai, N. Nukina, R. Takahashi and J.P. Julien, Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis, Nat Neurosci 9 (2006), 108-118.
51. O. Wirths, G. Multhaup and T.A. Bayer, A modified beta-amyloid hypothesis: intraneuronal accumulation of the betaamyloid peptide-the first step of a fatal cascade, J Neurochem 91 (2004), 513-520.
52. O. Wirths, G. Multhaup, C. Czech, V. Blanchard, S. Moussaoui, G. Tremp, L. Pradier, K. Beyreuther and T.A. Bayer, Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice, Neurosci Lett 306 (2001), 116-120.
53. S.H. Yoo, pH- and Ca(2+)-dependent aggregation property of secretory vesicle matrix proteins and the potential role of chromogranins A and B in secretory vesicle biogenesis, J Biol Chem 271 (1996), 1558-1565.
54. B. Zhang, Z. Tan, C. Zhang, Y. Shi, Z. Lin, N. Gu, G. Feng and L. He, Polymorphisms of chromogranin B gene associated with schizophrenia in Chinese Han population, Neurosci Lett 323 (2002), 229-233.